{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 45,
  "pageCount": 239,
  "prevPage": 44,
  "nextPage": 46,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "This is an activist short-seller report slide. It uses anecdotal evidence from KOLs to build a narrative of systemic failure.",
  "elementsJson": [
    "headline_text",
    "bullet_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/45",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-45",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Widespread lack of efficacy and explants, on top of other flaws unique to Nevro’s device, are the primary driver of Nevro’s ongoing collapse.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b339-b6ec0ea02d72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.86,
        "x": 0.08,
        "y": 0.31
      },
      "kind": "list",
      "text": "Case study #1: A high volume implanter described his initial experience as “almost miraculous,” only to sour after seeing rampant failures within 3-6 months.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1226ca94-66b2-4dc0-8d9b-fe6925bbf620",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.08,
        "y": 0.49
      },
      "kind": "list",
      "text": "Case study #3: One of the most prominent KOL’s in the field... described his initial enthusiasm for Nevro’s device only to see 75% of patients experience a quick collapse in efficacy.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58af6291-8a97-492b-9e02-e7d64ad9f6bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.08,
        "y": 0.72
      },
      "kind": "list",
      "text": "Case study #4: A fourth KOL corroborated the accuracy of these accounts based on his conversations with “hundreds of physicians”...",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71aa6773-49c4-4670-ab02-9404e7de1e2c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.08,
        "y": 0.8
      },
      "kind": "list",
      "text": "Case study #5: A fifth KOL, who spent time with Nevro’s CEO, began as “a 100% Nevro believer,” followed by rapid device failures and explants...",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7ede43c-639e-4843-b4aa-ff01a72d10e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.08,
        "y": 0.41
      },
      "kind": "list",
      "text": "Case study #2: A second KOL was also initially impressed with Nevro’s data, only to see patients fail “like clockwork.”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb68b80c-844f-4741-9978-eaa77a8c8370",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "The 33% explant rate in the NANS paper was corroborated by one KOL after another during our 20+ interviews... We share five detailed case studies of KOL's we interviewed...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0aa04092-4931-48e9-8733-8a5b816c3b46",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Nevro simply “can’t be used, based on the problems we’re seeing.” — KOL #4",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b339-b95c19accbde",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.25,
        "x": 0.06,
        "y": 0.1
      },
      "kind": "title",
      "text": "2. Summary of key findings",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5c86460-d844-4f60-93fc-71bb499533b8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7bd6ef0-6162-4a4e-b990-5bfb8b1f6166",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "antagonist-introduction",
      "slug": null,
      "matchId": "b22791fc-ca9f-4624-8c1a-53241306ed67",
      "evidence": "The slide frames Nevro as the antagonist through negative KOL testimonials.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 50,
      "from": 21,
      "beatId": "88afdd76-4cd8-403f-9d7e-4634fdd1d420",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Struggle",
      "beatSlug": "overcoming-monster-the-struggle",
      "evidence": "The deck details the struggles faced by Nevro's patients and the company's response",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}